Technology Platform Nutraceutical Development BM-A1 Clinical Trial Therapeutic Development Publications

BioMarker Completes the First Clinical Study of BM-A1 in Humans BioMarker has completed the clinical investigation of BM-A1, a combination botanical formulation, in human subjects.   This clinical investigation was a randomized, double-blind, placebo-controlled, parallel study.  According to the study design, the subjects were monitored for a wide range of health measures that could indicate whether safety or toxicity might be an issue. This study results demonstrated that BM-A1 was well tolerated, in relatively high doses, by all subjects.  No adverse events were reported that were associated with the ingestion of BM-A1. These results confirm the conventionally accepted tolerance and safety of this combination botanical product based on extracts of grape seed, Ginkgo biloba, and green tea. The positive safety outcome of BM-A1 clinical studies demonstrated our high degree of scientific expertise and commitment to the highest standards of pre-clinical and clinical development of such products.  With this first clinical study of a combination botanical product, BM-A1, BioMarker has now expanded its core competency in the molecular biological evaluation of nutritional products into the area of clinical investigation.  We will continue to devote significant resources and efforts to the development, testing and marketing of the highest quality nutritional products available to the consumer.